Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers February 6, 2016
Pharmacy Choice - News - U.S. Pharmaceutical Industry - February 6, 2016

Pharmacy News

 U.S. Pharmaceutical Industry
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

2/5/16 - "Pharmaceutical Composition of Doxycycline with Reduced Food Effect" in Patent Application Approval Process (USPTO 20160008379)
By a News Reporter-Staff News Editor at Drug Week A patent application by the inventors JAMI, Dileep; SINGH, Ravinder; FANDA, Anuj Kumar; SINGH, Romi Barat, filed on August 7, 2015, was made available online on January 21, 2016, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application has no
2/5/16 - Pharma bro Martin Shkreli keeps mum at House hearing, calls Congress imbeciles [Yerepouni Daily News (Lebanon)]
Pharmaceutical CEO Martin Shkreli the "most hated man in America," who raised the price of an HIV treatment 5,500 percent remained silent during a congressional hearing on prescription drug prices. Summoned before the House Oversight and Government Reform Committee to give testimony on his former company's recent increases in prices of prescr
2/5/16 - Acasti Announces Share-for-Debt
Acasti Pharma Inc., an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment of hypertriglyceridemia, announces the issuance of fifty thousand class A common shares as part of a settlement agreement executed on February 5, 2016.
2/5/16 - Aclaris Therapeutics to Present at the 2016 Leerink Partners Annual Global Healthcare Conference
Aclaris Therapeutics, Inc., a clinical-stage specialty pharmaceutical company, today announced that Dr. Aclaris Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company focused on identifying, developing, and commercializing innovative and differentiated drugs to address significant unmet needs in dermatology.
2/5/16 - Affinivax Secures Additional Funding to Advance its Novel Pneumococcal Vaccine towards Clinical Trials
Affinivax Inc., a biotechnology company dedicated to developing novel vaccines, today announced receipt of a $2.5 million investment from the Bill& Melinda Gates Foundation. This additional investment from the Gates Foundation validates the excellent progress we have made since we founded the company last year, said Steven B. Brugger, CEO of
2/5/16 - Allergan Announces FDA Approval of Updated Label for New Dosing Regimen for DALVANCE dalbavancin
By a News Reporter-Staff News Editor at Drug Week Allergan plc, a leading global pharmaceutical company, announced the U.S. Food and Drug Administration has approved the company's supplemental new drug application to update the label for DALVANCE for injection. "Hospitals are facing pressures to reduce hospitalizations and readmissions, while...
2/5/16 - Amarantus Requests Rare Pediatric Disease Designation from US FDA for MANF in the Treatment of Retinitis Pigmentosa
Amarantus BioScience Holdings, Inc., a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, announced that it has requested Rare Pediatric Disease Designation from the US Food and Drug Administration for treating retinitis pigmentosa with MANF. MANF was previously granted orphan drug...
2/5/16 - Big Pharma's worst nightmare
On a hot August afternoon in 2000, four Americans arrived for a secret meeting at the central London penthouse flat of an Indian billionaire drug manufacturer named Yusuf Hamied. A sixth person would join them there, a French employee of the World Health Organisation, who was flying in from Geneva, having told his colleagues he was taking leave.
2/5/16 - Biota Pharmaceuticals Reports Second Quarter Fiscal Year 2016 Financial Results
Biota Pharmaceuticals, Inc. today announced its financial results for the three month period ended December 31, 2015, which is the second quarter of the Company's 2016 fiscal year, and also provided an update on recent corporate developments.. I am very pleased today to report that significant progress is being made with our antiviral pipeline
2/5/16 - Blueprint Medicines Appoints Lonnel Coats to Board of Directors [Global Data Point]
Prior to joining Lexicon in July 2014, Mr. Coats served in a series of leadership positions at Eisai Inc. and Eisai Corporation of North America, U.S. subsidiaries of Tokyo- based Eisai Co., Ltd., from 1996 through June 2014, including as chief executive officer of Eisai Inc. from 2010 to June 2014.&# x0D;. In this role, Mr. Coats helped establish
2/5/16 - Boehringer Ingelheim - SPIRIVA RESPIMAT Now Available in the U.S. for Maintenance Treatment of Asthma in Adults and Adolescents
Release date- 04022016- Ingelheim, Germany,- Boehringer Ingelheim today announced that SPIRIVA RESPIMAT is now available for the treatment of asthma by prescription in U.S. pharmacies. 'Despite taking other daily maintenance treatments, many people with asthma continue to experience symptoms, including coughing, wheezing, shortness of breath,' said
2/5/16 - Califf, FDA top officials call for sweeping review of agency opioids policies [Global Data Point]
As one of the cornerstones of this plan, the FDA will seek guidance from outside experts in the fields of pain management and drug abuse. For example, the FDA has already asked the National Academy of Medicine to help develop a framework for opioid review, approval and monitoring that balances individual need for pain control with considerations of
2/5/16 - Canada Pharmaceutical Industry Report 2016
Dublin- Research and Markets has announced the addition of the "Canada Pharmaceutical Industry 2016" report to their offering. Canada also has the fourth fastest growing pharmaceutical industry after China, the US and Spain and has shown a steady growth trend. The pharmaceutical industry is one of the most innovative and profitable industries in Ca
2/5/16 - Canada Pharmaceutical Industry Report 2016 - Research and Markets
Research and Markets has announced the addition of the " Canada Pharmaceutical Industry 2016" report to their offering. Canada also has the fourth fastest growing pharmaceutical industry after China, the US and Spain and has shown a steady growth trend. The pharmaceutical industry is one of the most innovative and profitable industries in Canada.
2/5/16 - CoLucid Pharmaceuticals, Inc. (Nasdaq: CLCD) to Ring The Nasdaq Stock Market Closing Bell
What: CoLucid Pharmaceuticals, Inc., a Phase 3 clinical-stage biopharmaceutical company that is developing its lead product candidate, lasmiditan, for the acute treatment of migraine headaches, will visit the Nasdaq MarketSite in Times Square. Where: Nasdaq MarketSite 4 Times Square 43 rd& Broadway Broadcast Studio. Gal 3 C/06C 95.05 degre
2/5/16 - Concert Pharmaceuticals Assigned Patent
ALEXANDRIA, Va., Feb. 5 Concert Pharmaceuticals, Lexington, Massachusetts, has been assigned a patent developed by Roger D. Tung, Lexington, Massachusetts, for deuterated rigosertib. The patent application was filed on April 19, 2013. Written by Kusum Sangma; edited by Jaya Anand.
2/5/16 - Concert Pharmaceuticals Assigned Patent for Deuterated Derivatives of Ruxolitinib
ALEXANDRIA, Va., Feb. 5 Concert Pharmaceuticals, Lexington, Massachusetts, has been assigned a patent developed by five co-inventors for "deuterated derivatives of ruxolitinib." The co-inventors are I. Robert Silverman, Arlington, Massachusetts, Julie F. Liu, Lexington, Massachusetts, Adam J. Morgan, Ashland, Massachusetts, Bhaumik Pandya, Arling
2/5/16 - CPhI announces findings from its review of the US pharma manufacturing market
Overall, the review demonstrates that US pharma industry and domestic manufacturers are showing increased confidence of renewed growth...
2/5/16 - Eagle Pharmaceuticals, Inc. to Discuss Fourth Quarter and Full Year 2015 Financial Results on February 25, 2016
Eagle Pharmaceuticals, Inc. ( Eagle announced today that the Company will release its 2015 fourth quarter and full year financial results on Thursday, February 25, 2016, before the market opens. Eagle s strategy is to utilize the FDA's 505 (b) (2) regulatory pathway. Eagle Pharmaceuticals Investor Relations In-Site Communications Lisa Wils
2/5/16 - EDITORIAL: Big Pharma needs to rein in skyrocketing drug prices [Walla Walla Union-Bulletin, Wash.]
So it will be interesting to see how Congress will view these claims as it holds a hearing today on the recent dramatic price increases in pharmaceuticals. Former Turing Pharmaceuticals executive Martin Shkreli, who faces criminal charges on securities fraud, refused to answer questions under the Fifth Amendment protection. Last year, for example,
2/5/16 - Elite Pharmaceuticals, Inc. to Host Conference Call to Discuss 3rd Quarter 2016 Financial Results on February 10, 2016
Elite Pharmaceuticals, Inc., a specialty pharmaceutical company developing a pipeline of abuse-deterrent opioids and niche generic products, announced today that its third quarter financial results will be released on Tuesday, February 9, 2016. Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company which is developing a pipeline of...
2/5/16 - Falling off the patent cliff hurts UK drug maker
THE SO-CALLED patent cliff is fast approaching for pharma giant AstraZeneca as its warns that revenue and earnings could fall as rivals begin production on its money spinning cholesterol drug Crestor. The London- listed company is pinning its hopes on its pipeline of experimental drugs that are not expected to begin generating revenue in 2018. Astr
2/5/16 - Gene Therapy R&D and Revenue Forecasts 2016-2026
Prospects for Drugs Treating Cancer, Cardiovascular Disorders, Eye Conditions, Rare Diseases and Other Needs. Gene Therapies- Discover Revenue Predictions and See How Treating Cancer, Cardiovascular Disorders and Other Chronic Diseases Progresses What does the future hold for gene therapy? What progress and sales are possible?
2/5/16 - Give to Cure Adds Ability for Users to Give Through Venmo App
Give To Cure today announced that it is working with Venmo to allow users to search for and donate to Give To Cure's campaign that is crowdfunding clinical trials to help find cures faster for Alzheimer's Disease. In 2015 alone, Venmo processed $7.5 billion in transactions among users. Our model is about making science and social good accessible
2/5/16 - Global Psychiatry Partnering Deal Trends, Players and Financials Report 2010-2016
Dublin- Research and Markets has announced the addition of the "Global Psychiatry Partnering 2010-2016: Deal trends, players and financials" company profile to their offering. Global Sensory Organ Partnering 2010 to 2016 provides the full collection of Sensory Organ disease deals signed between the world's pharmaceutical and biotechnology companies
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2016 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Pharmacy Spanish
This lesson is supported by:
Hands on Spanish
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415